Johnson & Johnson
Change company Symbol lookup
Select an option...
JNJ Johnson & Johnson
MSI Motorola Solutions Inc
CCL Carnival Corp
MTWTF Metawater Co Ltd
ATRO Astronics Corp
HLT Hilton Worldwide Holdings Inc
MAIN Main Street Capital Corp
WIA Western Asset Inflation-Linked Income Fd
VST Vistra Corp
VRSN Verisign Inc

Health Care : Pharmaceuticals | Large Cap Value
Company profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Closing Price
Day's Change
0.99 (0.68%)
B/A Size
Day's High
Day's Low

10-day average volume:

Looking Ahead to the Q3 Earnings Season

4:14 pm ET September 9, 2020 (Zacks) Print

Note: The following is an excerpt from this week’s Earnings Trends report. You can access the full report that contains detailed historical actual and estimates for the current and following periods, please click here>>>

Here are the key points:

  • The overall earnings picture started improving in a notable way as Q3 got underway and the U.S. economy started recovering. Q3 earnings are still expected to be below the year-earlier level, but the projected rate of decline has improved relative to what was expected three months back.
  • For 2020 Q3, total S&P 500 earnings are expected to decline -23.9% on -3.3% lower revenues. This is an improvement from the -26.5% earnings decline expected at the start of July and follows the -32.7% earnings drop in Q2.
  • Sectors with the weakest Q3 growth outlook remain the social-distancing exposed spaces like Transportation (-128.8% earnings decline), Energy (-97.5%), and Consumer Discretionary (-89.2%).
  • 15 of the 16 Zacks sectors are expected to experience earnings declines in Q3, with the Construction sector as the only one expected to show earnings growth.
  • Medical (earnings decline of -0.1%), Utilities (-3.1%), Technology (-5.1%), and Retail (-7.8%) are the sectors with the lowest expected earnings declines in Q3.
  • Q3 earnings for the Finance, Industrial Products and Basic Materials sectors are expected to be down -25.7%, -27% and -31.1% from the year-earlier period, respectively.
  • For full-year 2020, total earnings for the S&P 500 index are currently expected to be down -20.9% on -4.9% lower revenues. As with Q3 estimates, full-year estimates have improved since early July. For reference, S&P 500 earnings declined -19.1% in 2008 and -3.4% in 2009, though that was admittedly a different type of downturn.
  • Growth is expected to resume next year, thanks to easy comparisons, but the dollar level of earnings in 2021 will still be below the 2019 level.
  • The implied ‘EPS’ for the S&P 500 index, calculated using current 2020 P/E of 26.3X and index close, as of September 8th, is $126.65, down from $160.15 in 2019. Using the same methodology, the index ‘EPS’ works out to $158.63 for 2021 (P/E of 21.0X). The multiples for 2020 and 2021 have been calculated using the index’s total market cap and aggregate bottom-up earnings for each year.
  • Please note that while full-year 2021 earnings for the S&P 500 index are currently expected to be up +25.2% from the 2020 level, the absolute dollar amount of 2021 earnings estimates remain below the 2019 level.
  • For the small-cap S&P 600 index, Q3 earnings are expected to be down -39.0% from the same period last year on -6.7% lower revenues, which would follow -64.7% decline on -21% lower revenues in 2020 Q2.
  • For full-year 2020, the S&P 600 index is expected to experience a -39.7% decline in earnings on -6.9% lower revenues, with easy comps pushing earnings growth to +41.9% in 2021.


The Q3 earnings season will really get underway after the big banks come out with quarterly results on October 20th. But we will have counted almost two dozen companies to have reported Q3 results by that time, as we and other data vendors consider companies reporting their fiscal quarters ending in August as part of the Q3 tally.

Using that definition, we will see Oracle (ORCL) kickstart the Q3 reporting cycle this week, followed by bellwethers such as Nike (NKE), FedEx (FDX), Adobe (ADBE) and others in the days to come.

The tone and substance of earnings releases notably improved in the Q2 earnings season relative to what we had seen in the Q1 reporting cycle. This improvement showed up in the revisions trend that we have been consistently pointing out, though the pace of improvement has slowed over the last few weeks. The chart below shows how estimates for Q3 evolved since early July.












We are seeing a similar improvement in estimates for Q4 2020 and full-year 2021 as well. The chart below shows the quarterly earnings and revenue growth picture.













The chart below shows the overall earnings picture on an annual basis.














The recent flow of economic readings has been broadly positive, suggesting that the hoped-for recovery is firmly in place. This is showing up in earnings estimates as well, as indicated earlier. The question at this stage is whether the improving trend can continue even as the underlying health issue remains unresolved.

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.3% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Oracle Corporation (ORCL): Free Stock Analysis Report
NIKE, Inc. (NKE): Free Stock Analysis Report
FedEx Corporation (FDX): Free Stock Analysis Report
Adobe Systems Incorporated (ADBE): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.